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Summary An immunoliposome containing a "'B-compound has been examined as a selective drug delivery
system in boron neutron-capture therapy. Liposomes, conjugated with monoclonal antibodies specific for
carcinoembryonic antigen (CEA) were shown to bind selectively to cells bearing CEA on their surface. The
immunoliposomes attached to tumour cells suppressed growth in vitro upon thermal neutron irradiation and
suppression was dependent upon the concentration of the "'B-compound in the liposomes and on the density
of antibody conjugated to the liposomes. The results suggest that immunoliposomes containing the '°B-
compound could act as a selective and efficient carrier of '°B atoms to target tumour cells in boron
neutron-capture therapy.
The application of neutron-capture therapy to cancer was
first reported by Locher (Locher, 1936). Kruger showed that
cancer cells could be killed in vitro by the application of
'°B-compounds with thermal neutron irradiation (Kruger,
1940). Cell destruction in boron neutron-capture therapy
(BNCT) is due to the nuclear reaction between '°B and
thermal neutrons to release alpha-particles (O He) and
lithium-7 ions (' Li). The 4 He kills cells in the range of 10gm
from the site of 4 He generation. Therefore, it is theoretically
possible to kill tumour cells without affecting adjacent heal-
thy tissues, if '°B-compounds could be selectively delivered.
BNCT has been applied to the treatment of malignant
brain tumours (Sweet, 1951; Hatanaka, 1986) or melanoma
(Mishima et al., 1983; 1989) by using '°B-compounds selec-
tively taken up by tumour cells. It would be possible to apply
BNCT for the treatment of various kinds of tumour, if
sufficient amounts of '°B-compound could be delivered to the
malignant cells by using monoclonal antibodies reactive to
these cells. Takahashi et al. (1987) prepared anti-alpha foeto-
protein monoclonal antibody conjugated with '0B-compound,
and this produced cytotoxic effects on hepatoma cells in
BNCT in vitro. However, in these experiments, antibody was
shown to lose activity by the direct conjugation with '°B-
compound.
Recently, liposomes have attracted attention as drug
delivery systems (Bangham et al., 1965; Hashimoto et al.,
1983; Konno et al., 1987; Tanaka, 1989). It is possible to
carry a large amount of '°B-compound in a liposome and,
therefore, the liposome could deliver a large amount of the
'°B-compound to a tumour cell, if it bears specific antibody
against the cells on the surface.
In the present experiments, we prepared a liposome which
contained '°B-compound and conjugated with a monoclonal
antibody specific for the tumour cells on its surface. The
immunoliposome was shown to deliver the '°B-compound to
target tumour cells and inhibit tumour cell growth on ther-
mal neutron irradiation in vitro.
Materials and methods
Target tumour cells
Human pancreatic carcinoma cell line AsPC-1 (Chen, 1982),
producing carcinoembryonic antigen (CEA) (Gold & Freed-
man, 1965), was obtained from Dainihon Seiyaku Co. Ltd.
(Osaka, Japan) and maintained in RPMI 1640 medium
(Hazleton Biologics, INC, Kansas, USA) supplemented with
10% foetal calf serum (Cell Culture Laboratories, Ohio,
USA) and 100 lg m'l kanamycin.
Preparation ofanti-human CEA monoclonal antibody
BALB/c mice were immunised intraperitoneally five times
with 1 x I07 AsPC-1 cells at intervals of 2 to 3 weeks. Four
days after the immunisation, spleen cells from these mice
were fused with mouse myeloma cells (X63, Ag8, 653) using
polyethylene glyco 4000 (Merk, Parnsteadt, Germany). After
2 weeks growth in selection medium containing hypoxan-
thine, aminopterine and thymidine, cells that produced anti-
CEA were selected by assaying the antibody in the medium
by enzyme-immunoassay and they were cloned three times by
a limiting dilution technique. A representative hybridome
clone, 2C-8, was selected, and grown in the peritoneal cavity
of the mouse. The antibody was purified on a DEAE-52
cellulose column (Whatmann, Biosystem Ltd, England) and
concentrated to 4 mg ml-'. A monoclonal antibody (MoAb)
specific for dinitrophenol (DNP) was used as a control.
Specificity of the antibody was confirmed by immunoperox-
idase staining of various cell lines. Seven cell lines known as
CEA-producers were all stained positive, although the inten-
sity of staining was variable, and eight non-producer cell
lines were not stained at all.
The epitope recognised by the antibody was confirmed to
be 200 kDa CEA and 45 kDa nonspecific crossreacting
antigen (NCA) by SDS PAGE and Western blotting using
the soluble antigen of AsPC-1 cells prepared according to
Laemmli methods (Laemmli, 1970), purified CEA purchased
from Kyouwa Hakkou Kougyo Co. Ltd. (Tokyo, Japan) and
purified NCA (Kleist et al., 1972) kindly provided by Dr T.
Sugiyama (Sapporo Medical College, Sapporo, Japan).
Immunocytological staining
Reactivity of monoclonal anti-CEA, 2C-8, to various cell
lines was examined by immunocytological technique de-
scribed by Hsu et al. (1981).
Briefly, the cells were fixed with acetone for 2 min at
-20°C. After incubation with 5% rabbit serum, the cells
were incubated for 60 min at room temperature with 2C-8
mouse ascites (1:200 dilution) or with immunoliposomes.
They were then washed in phosphate-buffered saline (PBS)
and incubated for 45 min with 1:50 diluted peroxidase-
conjugated rabbit antimouse IgGs (DAKO PATTS). The
preparations were visualised with diaminobenzine and
counterstained with haematoxylin.
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Chemicals
The caesium salt of undecahydro-mercaptocloso-dodeca-
borate (Cs2 '0B12H,,SH) was kindly supplied by Shionogi
Research Laboratories Co. Ltd. (Osaka, Japan). The solu-
bility of the compound in water was 250 mM at 40'C. N-
hydroxysuccinimidyl 3-(2-pyridyldithio)propionate (SPDP)
was purchased from Pharmacia Fine Chemicals (Uppsala,
Sweden). A stock solution of SPDP (30 mM) was prepared in
ethanol and stored at - 20'C. Dithiothreitol was obtained
from Sigma Chemical Co (St. Louis, MO, USA) and dis-
solved in water to a concentration of 3 mg ml-1.
Hen egg phosphatidylcholine (Egg PC) was a gift from
Nippon Fine Chemical Co. Ltd. (Osaka, Japan). Cholesterol
was obtained from Sigma Chemical Co. (St. Louis, MO,
USA). Dipalmitoylphosphatidylethanolamine (DPPE) was
from Calbiochem-Behring (San Diego, CA, USA). 3-(2-pyri-
dyldithio) propionyl- dipalmitoyl- phosphatidylethanolamine
(DTP DPPE) was prepared by reacting SPDP with DPPE as
described by Barbet et al. (1981).
Prepartion ofimmunoliposomes containing '°B-compound
Egg yolk PC (5 g moles), cholesterol (5fi moles) and DTP-
DPPE (0.25ytmoles) dissolved in chroloform-methanol (2:1)
were mixed in a conical flask. The organic solvent was
removed by evaporation at 40'C. A half ml of 25, 100,
250 mM '°B-compound (Cs210BI2H11SH) solution and 20 11
carboxyfluorescein (CF) (2timoles) were added to the dried
lipid film, and then multilamellar vesicles were prepared by
vortex dispersion. Uncapsulated '°B-compound and CF were
removed by washing with centrifugation at 20,000g. After
treatment for 30 min at room temperature with 20 mM dith-
iothreitol to ensure the functional SH-group, the liposome
was centrifuged at 20,000g. One ml of monoclonal antibody
(0, 0.5, 1.0, 4.0 mg ml-') was incubated with an excess
amount of SPDP for 30 min at room temperature. After
removal of free SPDP by passage through a Sephadex G 25
column, the liposomes were suspended in the antibody solu-
tion. After incubation at 4°C overnight, the boronated
immunoliposomes ('°B-Lip-MoAb) were washed by centrifug-
ation at 20,000g and suspended in I ml of 10mM veronal
buffer, pH 7.4, supplemented with 0.4% gelatin. An average
diameter of the liposome was estimated to be 4.7 jt in dyna-
mic light scattering analysis.
The liposome prepared was confirmed to be stable in
serum as reported (Yeagle, 1985), and boron was confirmed
not to leak out of the liposome.
The determination of'"'B-compound concentration entrapped in
liposomes
The amount of '°B-compound entrapped in liposomes was
determined by a colorimetric method in the presence of
curcumine (Ikeuchi & Amano, 1978).
After oxidative degradation with potassium permanganate,
boron was extracted with chloroform containing 2-ethyl-1,
3-hexanediol. Boron in the extract was converted into the
boron-curcumine complex by adding an acetic acid solution
of curcumine. Concentrated sulfuric acid was then added to
the solution. After dilution with 95% (v/v) ethanol, the
optimal absorbancy of the solution at 554 nm was measured
by spectrophotometry.
Thermal neutron irradiation
AsPC-1 cells, 5 x I04 cells/culture, were incubated in a 96
well-microplate at 37°C in 5% CO2 in air for 8 h in the
presence of immunoliposomes. After washing, the cells were
irradiated with thermal neutron at the TRIGA-Il atomic
reactor of Rikkyo University (Yokosuka, Japan). After
irradiation, 0.25ft Ci 3H TdR was added to each well and
incubated for further 8 h. Then, the cells were harvested and
the incorporation of thymidine was estimated in a liquid
scintillation spectrometer.
The determination ofgamma-ray dose generated at the thermal
neutron irradiation in the thermal column
The gamma-ray generated during thermal neutron irradiation
was measured using the ionisation chamber method (ICRU,
1964) at the irradiation points.
Gamma-ray irradiation ofcells
AsPC-1 cells were irradiated by gamma-rays from the '37Cs
source in Gamma Cell 40 (Atomic Energy of Canada,
Ottawa, Canada).
Results
Reactivity ofimmunoliposomes to target tumour cells
In order to examine the reactivity of immunoliposomes to
target cells, AsPC-l cells were incubated,with liposomes for
30min at room temperature, stained with second antibody
and examined under a microscope. The reaction was strongly
positive, when the'cells were incubated with the original or a
1:10 dilution of the liposome preparation. The cells were
stained weakly with the 1:100 dilution. Figure 1 shows
positive staining of the AsPC-1 cells with 1:10 dilution of the
liposome suspension. AsPC-l cells incubated with liposomes
conjugated with anti-DNP were not stained at all. The re-
activity of the immunoliposomes to AsPC-l cells was also
confirmed by the use of liposomes with fluorescent dye,
carboxyfluorescein (data not shown).
The concentration of'°B entrapped in liposomes
The immunoliposomes were prepared with 100 mM or 250
mM '°B-compound and 4 mg ml-' SPDP-anti-CEA. These
preparations were assayed for entrapped '°B. The amounts of
'°B in immunoliposomes prepared with 100 mM and 250 mM
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"'B-compound were 178± 33 and 623±80lagml-' liposome,
respectively. Anti-CEA conjugated with liposome was esti-
mated to be 734.0 ± 37ytg ml-' liposome. Thus, the lipo-
somes prepared with 100 mM and 250 mM "B compound
were calculated to contain 5.0 x 10' and 1.3 x I04 "'B for
each antibody, respectively. These results are shown as
averages and standard error of the values obtained from five
separate assays.
Growth inhibition ofAsPC-J cells treated with
immunoliposomes
In order to examine the effect of immunoliposomes on the
growth of AsPC-1 cells, the cells were treated with liposomes
prepared with 250 mM "'B-compound and 4 mg ml-l anti-
CEA or anti-DNP. After washing to remove free liposomes,
the cells were irradiated with various fluences of thermal
neutrons and cultured in vitro. As shown in Figure 2, AsPC-1
cells treated with the original suspension of immunolipo-
somes showed a reduction in growth by 50% at 1 x 1012
fluence or more of thermal neutrons. When AsPC-l cells were
treated with immunoliposomes prepared with anti-DNP ins-
tead of anti-CEA, they grew as well as untreated cells. As
shown in Figure 3, the decrement in cell growth was dependent
on the dose of the liposomes used, and liposomes without
antibody or "'B-compound exerted little effect on cell growth.
These results indicate that immunoliposomes could carry
"'B-compound to the target cells and exert toxic effects on
thenm.
Effect of'°B-compound concentration in immunoliposomes on
cytotoxicity
In order to confirm the role of "'B-compound in the immuno-
liposome, the effect of '°B-compound concentration on the
cytotoxicity of the liposome against AsPC-l cells was exam-
ined. Liposomes were prepared by using 25, 100, 250mM or
without '°B-compound and conjugated with 4 mgml-' anti-
CEA. These immunoliposomes were examined for their cyto-
toxic effects on AsPC-1. As shown in Figure 4, the liposomes
prepared in 25 mM "'B-compound showed little effect on
AsPC-I cell growth. However, liposomes prepared with 100
mM or 250 mM "'B-compound significantly inhibited the
growth of the cells and those prepared with "'B-compound
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Figure 2 Effect of thermal neutrons in vitro on AsPC-1 cells
treated with "'B-Immunoliposome (B-Lip-MoAb). The immuno-
liposomes were prepared by using 250mM 'OB-compound and
4 mg ml-' anti-CEA or anti-DNP. Cytotoxicity was estimated by
3H-TdR incorporation. Each point represents the mean±s.e. of
triplicate assay. "'B-Immunoliposome conjugated with anti-CEA
(0 0) or anti-DNP (0- -0). Medium only (X.X) or
"'B solution (500 ppm) (A -A-/) are also shown.
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Figure 3 Growth inhibiton of AsPC-1 cells treated with "'B-
immunoliposome ("'B-Lip-MoAb). AsPC-l cells were treated with
various concentrations of liposomes prepared with 250rmM "'B-
compound and conjugated with 4mgml-' anti-CEA or treated
with plain liposomes, washed and irradiated with thermal neu-
trons. AsPC-1 cell growths treated with undiluted (0 0),
diluted 1:100 (A---A) or 1:1000 diluted (0 -O) 'B-
Lip-MoAb, and also with undiluted (0 *), 1:1000 diluted
(A --A) or 1:1000 diluted (E---*) plain liposomes are
shown. The growth ofirradiated cells without liposome treatment
(X.X) is also shown.
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Figure 4 Effect of "'B-compound concentration in immuno-
liposomes on cytotoxicity. The growth of AsPC-1 cells treated
with liposomes prepared with 25 (A A), 100 (0--O),
250 mM (0 0) or without "'B-compound (0- --0) and
conjugate with 4 mg ml-' of anti-CEA and irradiated with ther-
mal neutrons is shown. The growth of irradiated cells without
liposome treatment (X.X) is also shown.
under 100 mM and greater than 25 mM may have recog-
nisable dose-dependent effectiveness.
These results indicate that the immunoliposomes must be
prepared with a concentration of 100mM or more of '°B-
compound for effective BNCT under our experimental condi-
tions.
Effect ofantibody density on the cytotoxicity
Antibody on the liposomes plays a role in their carriage to
target cells. In the next experiments, therefore, liposomes
prepared with 250 mM "'B-compound were conjugated with
various concentrations of anti-CEA, and the effects of these
immunoliposomes on AsPC-1 cell growth were examined
after thermal neutron irradiation. As shown in Figure 5,
AsPC-l cells showed reduced growth at 1 x 1012 n cm-2 and
more of thermal neutron fluences as the increment of the
antibody concentration used for the preparation of immuno-
liposomes. These results indicate that the antibody used forIN VITRO BNCT AGAINST TUMOUR CELL GROWTH 525
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Figure 5 Effect of antibody density on liposomes on cyto-
toxicity. Liposomes (Lip) prepared with 250 mM '°B-compound
were conjugated with 0.5 mg ml-' (A A), 1.0 mg ml-'
(0 O), 4.Omgml-' (0 0) or without (0 --*)
anti-CEA. The effects of these immunoliposomes ('°B-Lip-MoAb)
on AsPC-1 cell proliferation were examined after thermal neutron
irradiation. The growth of irradiated cells without liposome treat-
ment (X.X) is also shown.
the preparation of immunoliposomes plays an essential role
in targeting the liposomes to tumour cells.
Effect ofgamma-rays generated by thermal neutrons
There is a possibility that the inhibition of AsPC-l cells
described above was actually due to the gamma-rays gener-
ated by thermal neutrons. As shown in Table I, cells
irradiated with thermal neutrons were also irradiated with
various doses of gamma-rays generated depending on the
neutron dose. These doses of gamma-rays did not exert any
inhibitory effect on AsPC-l cell growth. With 3.36 Gy
gamma-rays, growth of AsPC-1 cell was suppressed weakly
but significantly.
Failure ofinhibition of tumour cellgrowth with soluble
Cs2'°B,2H11SH
In order to examine the effects of soluble '0B-compound (Cs2
'B H SH) on the proliferation of AsPC- cells, the cells were
suspended in various concentrations of '°B-compound solu-
tion. After they were irradiated with 1 x 1012 to 5 x 1012
n cm-2 of thermal neutron, their growth was examined. As
shown in Table II, the soluble '°B-compound did not signi-
ficantly suppress the cell growth even at 2000 ppm (4 mM). If
all of the liposomes prepared by using 250 mm of "'B-
compound were lysed to release '°B-compound into culture
medium, it would make 312 ppm "'B-compound solution.
Table I Gamma-ray generated by thermal neutron irradiation and the
effect of the irradiation on tumour cell growth
Thermal neutron Dose of
fluences gamma-ray* Cell growth
(n cm2) (Gy) (% uptake of3H-TdR)
O 0 100
5 x 10"1 0.258 95.3± 9.0
1 x 1012 0.515 93.6± 7.0 P
2 x 1012 1.030 96.7± 18.0 (P<0.05)
5 x 1012 3.360 70.6± 2.0
*Dose ofgamma-ray at neutron irradiation site was measured by the
ionisation chamber method. 5 x I04 AsPC-1 cells/200 gll/culture were
irradiated by these doses ofgamma-ray from "7Cs source in a separate
experiment. After the irradiation, cell proliferation in 8 h was measured
bytheincorporation of3H-TdR. Results oncell growth are presented as
the mean ± s.e. in triplicate assays in terms of percentage of 'H-TdR
uptake of unirradiated AsPC-1 cells.
Table II Failure of tumour cell growth inhibiton with soluble '0B-
compound
Concentration of'°B Thermal neutronfluence (n cm2)
solution (ppm) 0 1 x 1012 2 x 101 5 x 1012
0 57264 53384 50044 36895
±7595 ± 1645 ±450 ±2852
500 58843 48353 49977 36717
± 1922 ± 1740 ±2095 ±3646
1000 51707 49702 47559 35661
±2274 ±2624 ± 5690 ± 1375
2000 52832 50528 48184 36501
±3440 ±3704 ± 1694 ±3115
AsPC-1 cells were suspended in various concentrations of soluble
'0B-compoundandirradiated with I x 1012 to 5 x 1012 ncm2ofthermal
neutrons and incubated for 8 h. Cell growth was assayed by the
incorporation of3H-TdRintheincubation. Theresultsareshownin the
mean± s.e. of triplicate assays.
Because the maximum '°B concentration entrapped in
immunoliposomes was 623 ppm, and an equal volume of
medium suspending target cells was added, the '0B-con-
centration in the medium must be reduced to half. These
results may rule out the possibility that soluble '°B-com-
pound in the medium emits alpha-particles by thermal neu-
tron irradiation thereby injuring the cells.
Discussion
Antibody reactive to tumour cells is one of the most useful
vehicles for ensuring selective accumulation of boron in
tumours.
The effect of the 'OB-conjugated antibody on tumour cell
growth in BNCT was reported first by Mizusawa et al.
(1982), Goldenberg et al. (1984). They conjugated 50 boron
atoms directly to an antibody molecule, but the antibody did
not work efficiently in BNCT.
It was estimated that 109'OB atoms are required to destroy
one tumour cell in BNCT (Alam et al., 1984). When anti-
body directly conjugated with '°B-compound was used in
BNCT, the quantity of 'OB atom delivered to a cell was
proportional to the density of cell surface antigen molecules.
According to Alam et al., an antibody has to be conjugated
with 103 '0B atoms to destroy a tumour cell with 106 epitopes
on its surface. One thousand, three hundred boron atoms
were reported to be conjugated to a molecule of monoclonal
antibody by using SPDP (Alam et al., 1985).
A monoclonal antibody against alpha-foetoprotein was
found to exert some cytotoxic effect on AH66 tumour cells in
BNCT in vitro (Takahashi et al., 1987). However, a heavy
boronation of antibody has been shown to markedly reduce
the antibody reactivity (Alam et al., 1985; Takahashi et al.,
1987) and the numbers of epitope on the tumour cell surface
have been estimated to be at most 106/cell (Tsukada et al.,
1982; Barth et al., 1990). These results indicate that mono-
clonal antibody directly conjugated with '0B-compound has
limited application in BNCT.
A liposome is a vesicle which could entrap various
materials, and a method of conjugating protein molecules on
the surface by SPDP was developed (Barbet et al., 1981).
Therefore, it is possible for liposomes to carry a large
amount of substance to the target cell surface, if the sub-
stance is entrapped in the liposome conjugated with mono-
clonal antibody specific against the cells. In fact, liposome-
bearing antibody against human P2-microglobulin was found
to bind specifically to human cells but not to murine cells
(Leserman et al., 1981). Immunoliposomes containing
actinomycin D were reported to exert cytotoxic effect in
mammary carcinoma cells in an experimental model (Hashi-
moto et al., 1983).
In experiments reported here, immunoliposomes suppress-
ed tumour cell growth in vitro after thermal neutron irradia-
tion.526 H. YANAGIE et al.
Suppression was dependent upon the concentration of en-
trapped '0B-compound and also upon the density of anti-
CEA conjugated with liposome. These results in in vitro
experiments suggest that an immunoliposome containing '°B-
compound could be applied in BNCT as an effective carrier
of '0B-compound to target cells, and the evaluation of the
system in in vivo experiments remains to be carried out. In
the present experiment, gamma-rays generated by thermal
neutron irradiation did not exert toxic effects on cell growth
at less than 3.36 Gy. Therefore, 1 x 1012 or 2 x 1012 n cm-2
flux of thermal neutron may be recommended for BNCT,
because inhibition ofcell growth by concomitant gamma-rays
was found to be negligible at these doses. The use of a more
powerful atomic reactor may permit generation of more
fluxes of thermal neutrons with less gamma-rays.
In the present experiments, immunoliposomes were found
to be potential tools for BNCT, but problems remain to be
solved before application to in vivo BNCT. First, lipid com-
ponents of liposomes should be studied more extensively. In
the present experiment, multilamellar liposomes were used,
since small unilamellar ones composed of our lipid compo-
nent were shown to be unstable in culture, although small
unilamellar liposomes could be suitable for BNCT. If heat-
sensitive liposomes (Sullivan & Huang, 1985) were used for
BNCT, treatment with hyperthermia could possibly be com-
bined with BNCT to improve the efficiency of targeting of
'0B to tumour cells. Secondly, the technique of conjugating
antibody to liposome has to be improved, since F(ab')2 frag-
ments seem to be better for targeting (Martin et al., 1981),
because depletion of the Fc fragment of the antibody mole-
cule can obviate trapping of the molecule by Fc receptors on
phagocytes or other cells.
However, the most important problem to resolve before
clinical application of BNCT with immunoliposomes is how
to carry the liposome specifically to the target tumour, or to
promote penetration of blood vessels to reach tumour cells.
It is conceivable that a complement component or some
other substance could be conjugated to promote permeability
of small blood vessels.
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